Merck sold $3.2 billion of its Covid oral antiviral treatment, driving first-quarter revenue growth - CNBC

Merck soundly beat Wall Street estimates for its top and bottom lines, reporting earnings of $2.14 per share on $15.9 billion in revenue.

Merck sold $3.2 billion of its oral antiviral treatment for Covid in the first quarter, fueling the company's strong revenue growth. Merck soundly beat Wall Street profit and revenue forecasts, repo… [+1401 chars]

full article...